Scholars Central

Conference abstractPublished 21 Mar 2019

Exploratory process development of a second generation beta-amyloid cleaving enzyme inhibitor

Authors: Bryan Li

Pfizer Inc.-Groton, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Alzheimer’s disease (AD) is widely believed to be related to the production and deposition of the beta-amyloid (Aβ). Thus, beta-amyloid cleaving enzyme (BACE1) inhibitors, that can reduce the production of the Aβ peptide, are promising candidates for the treatment of AD. Pfizer researchers discovered a potent, selective BACE1 inhibitor that displayed good safety, tolerability, and pharmacokinetics from early stage clinical trials. The compound also exhibited excellent brain penetration, and potent in vivo efficacy. The exploratory active pharmaceutical ingredient (API) support strategy and the process development will be discussed. In this presentation, the synthesis of the complex target molecule will encompass the greening of a chiral isoxazoline production, continuous flow chemistry of a critical heteroaryl bromide-metal exchange and telescoped heteroaryl anion addition, and the GMP endgame development in multiple clinical campaigns.

Subjects

Chemistry

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalOrganic Chemistry: Current Research
  • SubjectChemistry
  • BylineArticles whose byline prints “Bryan Li”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels